01/03/2026
The Impact of Polypharmacy Amongst the Elderly in the United Kingdom (C.Odeleye MPH).
Abstract
Polypharmacy, commonly defined as the use of five or more medications, is increasingly prevalent among older adults in the United Kingdom. National data reveal that nearly one in four individuals aged 85 and above are prescribed eight or more medications, reflecting the complexity of multimorbidity management. While polypharmacy can be clinically appropriate, its widespread occurrence raises concerns about adverse drug reactions, frailty, cognitive decline, hospitalisation, and mortality, alongside significant economic and ethical implications.
This paper examines the impact of polypharmacy among the elderly in the UK, analysing prevalence, risks, potential benefits, and policy responses. It highlights the tension between therapeutic necessity and overmedicalisation, critiques current NHS initiatives, and argues for a standardised national framework to embed deprescribing into routine practice. By situating the discussion within clinical, economic, and ethical contexts, the paper contributes to ongoing debates on how best to balance medical prog patient safety in an ageing society.
Introduction
Polypharmacy, commonly defined as the concurrent use of five or more medications, has become a pressing public health concern in ageing populations (Age UK, 2019). In the United Kingdom, demographic shifts have intensified this challenge: by 2025, more than 11 million people are aged 65 or older, with a significant proportion living with multimorbidity. Recent cohort studies indicate that nearly one in four adults over 85 are prescribed eight or more medications (Elhussein et al., 2025).
While polypharmacy can be clinically appropriate, especially in cases of multimorbidity, its prevalence raises concerns about adverse drug reactions, hospitalisation, frailty, and cognitive decline (Boateng et al., 2025). The NHS has reported escalating prescription costs, alongside evidence that inappropriate polypharmacy contributes to preventable admissions and mortality (Age UK, 2019). These trends highlight a tension between medical necessity and the risks of overmedicalisation.
This paper examines the impact of polypharmacy among the elderly in the UK, exploring its prevalence, risks, potential benefits, and policy responses. By situating the discussion within both clinical and ethical contexts, it aims to contribute to ongoing debates on how best to balance therapeutic necessity with patient safety in an ageing society.
Prevalence and Risks
Polypharmacy has become increasingly common among older adults in the UK, reflecting both demographic change and advances in medical treatment. More than one in ten people aged 65 and over are prescribed eight or more medications stress with prevalence rising sharply in those aged 85 and above (El Hussein et al., 2025). NHS expenditure on medicines reached £18.2 billion in 2017/18, representing a 40% increase compared to 2010/11, with over 60% of prescriptions dispensed to individuals aged over 60 (Age UK, 2019).
The clinical consequences are well documented. Adverse drug reactions are a leading cause of hospital admissions among older adults, contributing to frailty, falls, and cognitive decline (Boateng et al., 2025). Inappropriate polypharmacy has been linked to reduced functional independence and diminished quality of life. Economically, preventable hospitalisations and medication-related harm add millions in costs to the NHS annually. Ethical concerns also arise, as complex medication regimens may compromise patient autonomy, leaving older adults struggling to understand or manage their treatments (AWTTC, 2023).
Deprescribing and Policy Responses
Structured medication reviews, now embedded within NHS primary care contracts, provide opportunities for clinicians and pharmacists to reassess treatment regimens, identify potentially inappropriate medications, and engage patients in shared decision-making (Williamson et al., 2025). Evidence suggests that pharmacist-led interventions can reduce medication load without compromising clinical outcomes (Hung, Kim and Pavon, 2024).
Despite these advances, deprescribing remains inconsistently applied. Clinician reluctance often stems from concerns about destabilising chronic conditions or medico-legal liability. Patients may express anxiety about discontinuing long-standing medications, particularly when they perceive them as essential to survival. Fragmented care pathways further complicate efforts, as multiple prescribers across specialties may contribute to overlapping or conflicting regimens.
A more robust national framework for polypharmacy management is needed to ensure consistency and accountability. Such a framework should integrate deprescribing into routine practice, supported by clear clinical guidelines, training for healthcare professionals, and incentives for implementation. Person-centred care models, which prioritise patient values and preferences, can help overcome resistance by reframing deprescribing as a proactive, empowering process rather than a withdrawal of care (AWTTC, 2023).
Discussion
Polypharmacy among the elderly in the UK underscores a complex interplay between therapeutic necessity and potential harm. For many older adults, the concurrent use of several medications is clinically appropriate and can improve survival, particularly in cardiovascular disease and diabetes.
However, the risks associated with inappropriate polypharmacy remain substantial. Adverse drug reactions, falls, frailty, and cognitive decline are consistently linked to excessive or poorly coordinated prescribing (Boateng et al., 2025). The economic burden is equally significant, with preventable hospitalisations contributing to rising NHS costs. Ethical concerns also emerge, as older adults may experience diminished autonomy when faced with complex medication regimens.
Policy responses such as structured medication reviews and pharmacist-led interventions represent important steps forward, but implementation remains uneven. A national framework for polypharmacy management, supported by multidisciplinary teams, could provide greater consistency and accountability. Future research should prioritise longitudinal studies that capture patient outcomes over time, as well as qualitative work exploring patient perspectives on medication burden (El Hussein et al., 2025).
Ultimately, addressing polypharmacy requires a cultural shift: from viewing prescribing as the default response to illness, to embracing deprescribing as an equally valid and necessary aspect of care.
Conclusion
Polypharmacy among the elderly in the UK represents both a triumph of modern medicine and a pressing public health challenge. While multiple medications are often clinically necessary to manage multimorbidity, the prevalence of inappropriate polypharmacy has significant consequences for patient safety, autonomy, and healthcare costs. Current NHS initiatives are promising but require greater consistency and cultural acceptance.
Moving forward, a national framework that embeds deprescribing into routine practice, supported by multidisciplinary teams and patient-centred approaches, is essential. Future research should prioritise longitudinal outcomes, cost-effectiveness analyses, and patient perspectives. Ultimately, true quality of care lies in balancing therapeutic necessity with the dignity and safety of older adults.
References (Harvard Style)
• Age UK (2019) More harm than good: Why more isn’t always better with older people’s medicines. London: Age UK. Hung, A., Kim, Y.H. and Pavon, J.M. (2024) ‘Deprescribing in older adults with polypharmacy’, BMJ, 385, e074892.
• El Hussein, L. et al. (2025) ‘Longitudinal trajectories of polypharmacy in older people, and their association with the risk of mortality’, Age and Ageing, 54(8), afaf233.
• Boateng, I. et al. (2025) ‘The impact of polypharmacy on health outcomes in the aged: A retrospective cohort study’, PLOS One, 20(2), e0317907.
• Williamson, S. et al. (2025) Polypharmacy and deprescribing: Insights pack. Hertfordshire and West Essex Integrated Care System.
• All Wales Therapeutics and Toxicology Centre (AWTTC) (2023) Polypharmacy in older people: A guide for healthcare professionals. Cardiff: NHS Wales.
Editor-in-Chief
Age and Ageing
Oxford University Press
2 December 2025.
